Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Reduced immunostaining for the extracellular Ca{sup 2+} - sensing receptor in primary and uremic secondary hyperparathyroidism

Journal Article · · Journal of Clinical Endocrinology and Metabolism
; ;  [1]
  1. Brigham and Women`s Hospital, Boston, MA (United States); and others

Most parathyroid adenomas and some pathological parathyroid glands from patients with primary parathyroid hyperplasia or severe uremic secondary/tertiary hyperparathyroidism show an elevated set-point. In the present study, we investigated whether expression of the Ca{sup 2+}{sub o}-sensing receptor protein recently cloned from bovine parathyroid, a key component in Ca{sup 2+}{sub o}-regulated PTH release, is altered in primary and uremic hyperparathyroidism. Using immunohistochemistry with specific antireceptor antibodies, we compared immunoreactivity of the receptor protein in 14 adenomas, biopsies of 24 normal glands from this same group of patients, and 8 hyperplastic parathyroid glands from 2 individuals with uremic hyparathyroidism. The results show a substantial reduction in the intensity of immunostaining for the receptor protein that averaged nearly 60% for both adenomas and hyperplastic glands, as quantitated by image analysis. There was considerable variation in staining intensity among different pathological parathyroid glands, even in those from the same patient with secondary hyperparathyroidism. In addition, both adenomas and hyperplastic glands had, in some cases, isolated chief cells and groups of cells, sometimes around the periphery of an abnormal gland, with receptor staining equivalent to that of normal parathyroid cells, whereas the bulk of the cells in the same gland showed a marked decrease in staining. Thus, there is a variable, but substantial, reduction in the immunoreactivity of the Ca{sup 2+}{sub o}-sensing receptor protein in both parathyroid adenomas and uremic hyperparathyroidism, as assessed by immunohistochemistry, that probably results from reduced expression of the receptor protein and may contribute to the increase in the set-point often observed in these patients. 49 refs., 8 figs., 1 tab.

OSTI ID:
530766
Journal Information:
Journal of Clinical Endocrinology and Metabolism, Journal Name: Journal of Clinical Endocrinology and Metabolism Journal Issue: 4 Vol. 81; ISSN JCEMAZ; ISSN 0021-972X
Country of Publication:
United States
Language:
English

Similar Records

Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11
Journal Article · Thu Dec 31 23:00:00 EST 1992 · Journal of Clinical Endocrinology and Metabolism; (United States) · OSTI ID:6827940

Localization of enlarged parathyroid glands by thallium-201 and technetium-99m subtraction imaging. Gland mass and parathormone levels in primary hyperparathyroidism
Journal Article · Sun Mar 31 23:00:00 EST 1985 · Clin. Nucl. Med.; (United States) · OSTI ID:5096707

Hyperparathyroidism after radioactive iodine therapy for Graves disease
Journal Article · Sun Oct 31 23:00:00 EST 1982 · Surgery; (United States) · OSTI ID:6622144